Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Accumulated Expenses (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Other Accumulated Expenses for 6 consecutive years, with $551000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $551000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $551000.0, a N/A change, with the full-year FY2024 number at $918000.0, up 67.21% from a year prior.
  • Other Accumulated Expenses was $551000.0 for Q3 2025 at Janux Therapeutics, down from $587000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $925000.0 in Q1 2025 to a low of $478000.0 in Q4 2021.
  • A 5-year average of $643500.0 and a median of $569000.0 in 2025 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: dropped 11.88% in 2023, then skyrocketed 67.21% in 2024.
  • Janux Therapeutics' Other Accumulated Expenses stood at $478000.0 in 2021, then soared by 30.33% to $623000.0 in 2022, then decreased by 11.88% to $549000.0 in 2023, then soared by 67.21% to $918000.0 in 2024, then plummeted by 39.98% to $551000.0 in 2025.
  • Per Business Quant, the three most recent readings for JANX's Other Accumulated Expenses are $551000.0 (Q3 2025), $587000.0 (Q2 2025), and $925000.0 (Q1 2025).